嵌合抗原受体
免疫疗法
癌症免疫疗法
癌症研究
抗原
免疫学
免疫抑制
医学
T细胞
T细胞受体
肿瘤抗原
免疫系统
细胞毒性T细胞
过继性细胞移植
癌症
肿瘤微环境
出处
期刊:Recent Patents on Anti-cancer Drug Discovery
[Bentham Science]
日期:2019-03-13
卷期号:14 (1): 60-69
被引量:1
标识
DOI:10.2174/1574892814666190111120908
摘要
Background: Chimeric Antigen Receptor (CAR) T cell immunotherapy, as an innovative method for tumor immunotherapy, acquires unprecedented clinical outcomes. Genetic modification not only provides T cells with the antigen-binding function but also endows T cells with better immunological functions both in solid and hematological cancer. However, the CAR T cell therapy is not perfect because of several reasons, such as tumor immune microenvironment, and autologous limiting factors of CAR T cells. Moreover, the safety of CAR T cells should be improved. Objective: Recently many patents and publications have reported the importance of CAR T cell immunotherapy. Based on the patents about CAR T cell immunotherapy, we conclude some methods for designing the CAR which can provide information to readers. Methods: In this review, we collect recent patents and publications, summarize some specific antigens for oncotherapy from patents and enumerate some approaches to conquering immunosuppression and reinforcing the immune response of CAR T cells. We also sum up some strategies for improving the safety of CAR T cell immunotherapy. Results: CAR T cell immunotherapy as a neotype cellular immunotherapy has been proved effective in oncotherapy and authorized by FDA. Improvements in CAR designing enhance functions of CAR T cells. Conclusion: This review, summarizing antigens and approaches to overcome defects of CAR T cell immunotherapy from patents and publications, might contribute to a broad readership.
科研通智能强力驱动
Strongly Powered by AbleSci AI